Navigation Links
Experimental Pill for Multiple Sclerosis Shows Promise
Date:4/16/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, April 16 (HealthDay News) -- An experimental pill reduced the number of lesions in the brains of people with multiple sclerosis (MS), researchers report.

The drug, which currently goes by the name ONO-4641, "actually caused a reduction in relapses, which is somewhat unusual in a study this small and is quite encouraging," said lead researcher Dr. Timothy Vollmer, a professor of neurology and medical director of the Rocky Mountain MS Center, located at the University of Colorado, in Denver.

The medication is also "more selective than other drugs in its class and hopefully that will provide a better safety profile long-term," Vollmer said. He added that the aim of the therapy is to prevent MS-linked disability and prevent brain damage.

"We are shifting our therapeutic goals. We are no longer interested in just slowing the disease, we are actually interested in putting patients into what we call a 'disease activity-free' state," he explained.

"And in some patients, with these highly effective therapies, our goal is to induce a remission of symptoms and that's doable in patients with early disease. The goal is going to treat early and aggressively to prevent brain injury," Vollmer said.

The results of the phase 2 clinical trial were released April 16 and will also be presented next week at the American Academy of Neurology's annual meeting in New Orleans.

Commenting on the study, Dr. Gary Birnbaum, director of the Multiple Sclerosis Treatment and Research Center at the Minneapolis Clinic of Neurology, said that ONO-4641,"appears to be similar in mechanism of action to the approved drug, fingolimod (Gilenya), but appears to be more selective in its action."

Nevertheless, based on the recent post-marketing reports of sudden death in patients on fingolimod, and the data reported in this trial of slowed heart rate in patients receiving ONO-4641, similar safety concerns may arise with this drug, Birnbaum said.

"In addition, the drug induces a lymphopenia [low white blood cell count], indicating it too is an immune suppressant. Immune suppression has its own dangers, as noted with fingolimod, where two patients died of liver infections, and there was an increased risk of skin cancer," Birnbaum said.

More study is needed to assess the long-term effectiveness and safety of ONO-4641, he said.

"At first glance, the drug appears to reduce central nervous system inflammation, but data on reducing [MS] disease progression and long-term safety will be needed to assess the final value of this drug," Birnbaum said.

For the trial, investigators randomly assigned 407 people aged 18 to 55 with relapsing-remitting MS to one of three daily doses of the drug or placebo. Patients underwent brain scans once every month between weeks 10 and 26 of treatment.

After 26 weeks, Vollmer's group found that compared to those taking a placebo, patients on the low dose of ONO-4641 experienced an average 82 percent reduction in what experts call "MS-enhancing brain lesions."

For those receiving the middle dose the reduction was 92 percent and for those on the high dose, 77 percent, they found.

Adverse events were related to the dose of the drug patients received and included cardiovascular events such as a slower heartbeat, blood pressure changes or other heart problems.

Other side effects included liver-enzyme elevations. In addition, lymphopenia occurred in 4 percent of people receiving the high dose of ONO-4641 and in 1 percent of those receiving the middle dose, the researchers note.

The study was supported by the drug's maker, Ono Pharmaceutical Co., Ltd.

Another expert, Nicholas LaRocca, vice president for health care delivery and policy research at the National MS Society, said that "MS is a complex disease that affects each person differently and so it is important for people with MS to have access to a variety of options for safe and effective therapies."

"Based on this phase 2 study, ONO-4641 appears promising and so we look forward to the results of larger studies of this new agent," he said.

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

To learn more about MS, visit the National Multiple Sclerosis Society.

SOURCES: Timothy Vollmer, M.D., professor, neurology and medical director, Rocky Mountain MS Center, University of Colorado, Denver; Gary Birnbaum, M.D., director, Multiple Sclerosis Treatment and Research Center, Minneapolis Clinic of Neurology, Minneapolis; Nicholas LaRocca, Ph.D., vice president for health care delivery and policy research, National MS Society; April 16, 2012, presentation, American Academy of Neurology's 64th Annual Meeting, New Orleans


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Experimental Pill May Ease Multiple Sclerosis Disability
3. Experimental Drug Shows Promise Against Cushings Disease
4. Experimental Drug Offers Hope for Rare Bone Disease: Study
5. Experimental Drug Shows Promise Against Type 2 Diabetes
6. First-in-human drug for malignant glioma available in experimental trial
7. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
8. Experimental Drugs Do Battle Against Advanced Prostate Cancer
9. Experimental Blood Thinner Given Before Surgery Shows Benefit
10. Wolfson Foundation awards £20 million to UCL for experimental neurology center
11. Novel experimental agent is highly active in CLL patients, interim study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Pill for Multiple Sclerosis Shows Promise
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from Healing ... cluster of melanin when exposed to sunlight. Although most moles are benign and harmless, ... Historically, mole removal has involved a painful, often expensive visit to the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016   GS1 US will ... guide them through GS1 Standards implementation to address the ... Unique Device Identification (UDI) rule. Scott ... Beth Gibson , senior director industry development, medical devices, ... director, GS1 US --> Scott ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
Breaking Medicine Technology: